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Abstract
In mice deprived of food for 12 h, the i.c.v. or i.p. administration of benzylamine, a substrate common to both monoamine oxidase B
and semicarbazide-sensitive benzylamine oxidases, dose-dependently inhibited feeding. This effect was significantly potentiated by
selective monoamine oxidase A and B inhibition, suggesting that central monoamines, known to be substrates of these enzymes may be
 .released. The i.p. administration of semicarbazide-sensitive benzylamine oxidase inhibitors, B24 3,5-ethoxy-4-aminomethylpyridine and
 . .MDL 72274 E -2-phenyl-3-chloroallylamine strongly potentiated the effect of i.p. but not i.c.v.-administered benzylamine. The
hypophagic effect of benzylamine was evaluated following i.c.v. administration, in comparison with the effect of the sympathomimetic
compound amphetamine or the Kq channel blocker tetraethylammonium, as reference compounds. Our results make it possible to define
benzylamine as a centrally acting hypophagic compound devoid of amphetamine-like motor stimulatory effects and point to a role of B24
and MDL 72274 as specific peripheral enhancers of the pharmacological effects of benzylamine. q 2001 Elsevier Science B.V. All rights
reserved.
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1. Introduction
The metabolism of monoamines in mammalian tissues
is catalyzed by different amine oxidases, among which
monoamine oxidase amine:oxygen oxidoreductase; EC
.1.4.3.4 and semicarbazide-sensitive benzylamine oxidases
 .EC 1.4.3.6 . Monoamine oxidases are found as A or B
isoenzymes, each one with different affinities for sub-
strates and sensitivity to inhibitors. Monoamine oxidase A
is selectively inhibited by clorgyline, and preferentially
metabolizes noradrenaline, tyramine and 5-hydroxytryp-
 .tamine 5-HT . Monoamine oxidase B deaminates the
biogenic amines b-phenylethylamine, dopamine or benzy-
lamine and is selectively inhibited by L-deprenyl Knoll,
.1998 .
Tissue semicarbazide-sensitive benzylamine oxidases
are copper-containing enzymes which deaminate endoge-
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nous and exogenous monoamines, and share the xenobiotic
 .substrate benzylamine Buffoni, 1995 with monoamine
oxidase B. Little is known at present of the physiological
role of semicarbazide-sensitive benzylamine oxidases. Be-
cause these enzymes are present in brain microvessels
Lewinson et al., 1978; Buffoni, 1993; Castillo et al.,
.1998 in plasma and peripheral vascular tissues, it has been
suggested that they might have a protective role against
toxic monoamines absorbed exogenously. Conversely, it
has been established that semicarbazide-sensitive benzy-
lamine oxidases could have a role in the cardiovascular
damage induced by aldehydes deriving from the oxidative
deamination of allylamine Boor and Nelson, 1980; Ramos
. et al., 1988 or methylamine Yu and Dong-mei Zuo,
.1993; Deng and Boomsma, 1998 .
Highly selective and potent semicarbazide-sensitive
benzylamine oxidase inhibitors are presently available,
among which are the competitive and reversible 3,5-
 . ethoxy-4-aminomethylpyridine B24 Banchelli et al.,
.  .1990 , and the non-competitive and irreversible E -2-
 . phenyl-3-chloroallylamine MDL 72274 Lyles et al.,
.1987; Banchelli et al., 1994 . By using a compound struc-
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turally related to MDL 72274, it has been demonstrated
that some pharmacological effects of benzylamine in the
isolated arterial bed could be potentiated Elliot and Call-
.ingham, 1991 , confirming that selective inhibitors of
semicarbazide-sensitive benzylamine oxidases may be im-
portant tools for clarifying the role of these enzymes.
However, so far, most pharmacological results with selec-
tive inhibitors have been obtained in Ain vitroB experi-
ments, while pharmacological evidence regarding the role
of semicarbazide-sensitive benzylamine oxidase enzymes
Ain vivoB is scarce.
Feeding behavior is a central function that is profoundly
affected by different neurotransmitters, including dopamine
and 5-HT Abdallah et al., 1976; Moreley and Levine,
.1985; Parada et al., 1992; Curzon et al., 1997 . It is
well-known that indirectly acting compounds, with differ-
ent mechanisms of action, can profoundly influence this
function. For example, indirectly acting drugs, such as the
dopamine-releasing agent, amphetamine or the 5-HT re-
leasing agent, fenfluramine Cole, 1978; Aulakh et al.,
.1988; Parada et al., 1992 , act as central anorectic com-
pounds by increasing the release of dopamine or 5-HT
respectively. On the other hand, Kq channel blockers can
 .reduce feeding behavior Ghelardini et al., 1997 , and
induce the central release of dopamine or 5-HT acting as
depolarizing compounds in the neurons Cook and Quast,
.1990; Dawson and Routledge, 1995; Schechter, 1997 .
Recently, we have observed that benzylamine and some
related compounds stimulate sympathetic rat vas deferens
neurotransmission and potentiate memory in the mouse. In
their activity, they resemble the indirectly acting com-
pound, amphetamine, or the Kq channel blocker, tetra-
ethylammonium Pirisino et al., 1993; Banchelli et al.,
.2000 . Therefore, to clarify the role of semicarbazide-sen-
sitive benzylamine oxidase enzymes in the modulation of
the central stimulating activity of benzylamine, we decided
to assess the effect of this compound on feeding behavior
in mice. In the present work, we compared the activity of
benzylamine to that of tetraethylammonium and am-
phetamine. To evaluate the central or peripheral role of the
various classes of amine oxidases in modulating the activ-
ity of these compounds, we decided to administer them as
i.c.v. or i.p. injections in animals pretreated with the
semicarbazide-sensitive benzylamine oxidase inhibitors,
B24 and MDL 72274, or with clorgyline and deprenyl, in
order to selectively inhibit monoamine oxidase A and B,
respectively.
2. Materials and methods
2.1. Animals
 .Male Swiss albino mice 23–30 g from the Morini
 .San Polo d’Enza, Italy breeding farm were used. Fifteen
mice were housed per cage. The cages were placed in the
room of the experiment 24 h before the test for adaptation.
The animals were kept at 23"18C with a 12 h light–dark
cycle, lights on at 7:00 a.m., and were fed a standard
laboratory diet with water ad libitum. All experiments
were carried out in accordance with the European Commu-
nities Council Directive of 24 November 1986 86r609r
.EEC for experimental animal care.
2.2. Tissue samples to assess AO inhibition
To obtain selective inhibition of monoamine oxidase A
and B activities in mouse brain, we administered 2.5
mgrkg i.p. clorgyline or 10 mgrkg deprenyl Finnegan et
.al., 1995 . With regard to the dosage regimen of MDL
72274 as selective inhibitor of semicarbazide-sensitive
 y1 .benzylamine oxidases, the same dosage 2.5 mg kg i.p.
previously found to be selective for these enzymes in rats
 .was given i.p. to the mice Banchelli et al., 1994 .
Three hours after the injection of saline, clorgyline,
deprenyl or MDL 72274 the mice were killed and the
brains and the epidydimal white adipose tissue were re-
moved and stored at y708C for monoamine oxidase A and
B and semicarbazide-sensitive benzylamine oxidase assay.
The homogenates were prepared in 10 volumes of K–Na-
 .phosphate buffer 0.1 M pH 7.4 , using a hand-held ground
glass homogenizer.
2.3. Amine oxidase acti˝ity
The assay samples contained 50 ml homogenate, 50 ml
buffer and 50 ml radioactive substrate. Homogenates were
preincubated for 20 min at 378C prior to substrate addition.
Mixtures containing substrate were then incubated at 378C
for 10 min, to ensure the linear formation of metabolites.
Assays were stopped with 50 ml 3 N HCl, and radiola-
belled metabolites were extracted into 0.7 ml ethyl acetate;
 .some 0.5 ml of this extract was counted in a Packard
1900 TR liquid scintillator. Monoamine oxidase A and B
w14 x w14 xactivities were determined by using C 5-HT and C
benzylamine 0.5 mM, respectively, as specific substrates
for these enzymes. Semicarbazide-sensitive benzylamine
w14 xoxidase activity was assayed by using C benzylamine
20 mM in the presence of high-concentration deprenyl 1
.mM to inhibit monoamine oxidase activity. Enzymatic
activity was expressed as the amount of product formed
per hour per gram of tissue wet weight.
2.4. Intracerebro˝entricular injection technique
 .Intracerebroventricular i.c.v. administration was per-
formed under ether anesthesia, according to the method
 .described by Haley and McCormick 1957 . Briefly, dur-
ing anesthesia, the mice were grasped firmly by the loose
skin behind the head. A 0.4-mm external diameter hypo-
dermic needle attached to a 10-ml syringe was inserted
perpendicularly through the skull, no more than 2 mm into
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the brain of the mouse, where 5 ml was then administered.
The injection site was 1 mm to the right or left from the
midpoint, on a line drawn through to the anterior base of
the ears. Drugs were injected randomly into the right or
left ventricle. To ascertain that the drugs were adminis-
tered exactly into the cerebral ventricle, some mice were
injected with 5 ml of 1:10 diluted India ink and their brains
were examined macroscopically after sectioning.
2.5. E˝aluation of food consumption
The mice were food-deprived for 12 h, although water
was available ad libitum. A weighed amount of food
 .standard laboratory pellets was given, and the weight
consumed evaluated as the difference between the original
.amount and the food left in the cage, including spillage
was measured 15, 30, 45 and 60 min after injection, with
an accuracy of 0.1 g. An arbitrary cut-off time of 60 min
was used.
2.6. Rota rod test
The apparatus consisted of a base platform and a rotat-
ing rod with a diameter of 3 cm and a non-skid surface.
The rod was placed at a height of 15 cm from the base.
The rod, 30 cm in length, was divided into five equal
sections by six disks. Then, up to five mice were tested
simultaneously on the apparatus, with a rod rotation speed
of 16 rpm. The integrity of motor coordination was as-
sessed on the basis of the number of falls from the rod in
 .30 s, in accordance with Vaught et al. 1985 . Performance
time was measured before and 15, 30, 45 and 60 min after
the i.c.v. administration of saline or drug solutions.
2.7. Drugs
Deprenyl hydrochloride, clorgyline hydrochloride, ben-
zylamine hydrochloride, amphetamine sulfate, tetraethyl-
w  .ammonium HCl, Ro 16-6491 N- 2-aminoethyl -p-chloro-
xbenzamide HCl and a-methyl-p-tyrosine methyl ester were
 .purchased from Sigma St. Louis, MO, USA . WAY
 w  . x 100635 N- 4- 2-methoxyphenyl -1-piperazinyl -N- 2-
. 4pyridinyl cyclo-hexanecarboxamide was obtained from
w 14 xRBI SigmarAldrich, Milan. 7- C benzylamine hydro-
 y1 . w 14 xchloride 57 mCi mmol and 5-hydroxy 2- C trypta-
 y1 .mine 50 mCi mmol were obtained from Amersham
 .Pharmacia Biotech Italia 20138 Milan . MDL 72274 was
a gift of the Marion Merrell Dow Research Institute Stras-
.bourg Cedex, France . B24 was synthesized by Prof. V.
Bertini Department of Organic Chemistry of the Univer-
.sity of Genoa .
 .The drugs were dissolved in isotonic NaCl 0.9%
saline solution and their pH value was checked; drug
concentrations were prepared in such a way that the neces-
sary dose could be administered in a volume of 5 mlrmouse
by i.c.v. injection and 10 ml kgy1 by i.p. injection.
2.8. Statistical analysis
All experimental results are expressed as the means"
 .S.E.M. Analysis of variance ANOVA , followed by
 .Fisher’s Protected Least Significant Difference PLSD
procedure for posthoc comparison, were used to verify the
significance of differences between two means. Data were
analyzed using the StatView software for the Macintosh
 .1992 . Fitting of the sigmoid dose–response curves, as
well as ED , K and V , were obtained from a non-lin-50 m max
ear regression analysis Prism program, GraphPad Soft-
.ware, San Diego, CA .
3. Results
3.1. Amine oxidase inhibition
Because of the lack of information on the inhibitory
effect of MDL 72274 on semicarbazide-sensitive benzy-
lamine oxidase activity in mice, its inhibition kinetics were
studied in the epidydimal white adipose tissue. In this
tissue, MDL 72274 showed IC values very similar to50
 y8 y9those previously observed in rats 1.7=10 and 2=10
.M in mice and rats respectively; ns5 . The apparent Km
values of semicarbazide-sensitive benzylamine oxidase-de-
w14 xpendent oxidative deamination of C benzylamine did
not vary in the controls and in MDL 72274-treated ho-
 .mogenates 63"10 and 58"14 mM, respectively ; on
the contrary V values were significantly reduced inmax
control and in MDL 72274-treated samples 43"5 and
y1 y1 .20"5 nmol mg min ; P-0.05 . Together these re-
sults confirm that this inhibitor has similar activity in
mouse and rat semicarbazide-sensitive benzylamine oxi-
 .dases Banchelli et al., 1994 .
In order to ascertain whether a selective amine oxidase
inhibition was obtained in mice during experiments on
feeding behavior, we assayed monoamine oxidase A, B
and semicarbazide-sensitive benzylamine oxidases in the
whole brain homogenates of these animals. After the i.p.
administration of MDL 72274, both monoamine oxidase A
 .and B activities were unaffected Fig. 1 , while clorgyline
and deprenyl inhibited these enzymes by 92% and 93%,
respectively. A very low activity of semicarbazide-sensi-
tive benzylamine oxidases in the mouse brain homogenates
was measured which probably was due to microvessels
 .Castillo et al., 1998 . Under these conditions, however,
w14 xthe deamination of C benzylamine, still present after
 .high deprenyl concentrations 1 mM , was significantly
 y1 y1reduced controls s 92.8 " 13 nmol g h ; MDL
72274-pretreateds49.3"11 nmol gy1 hy1 ; P-0.05;
.ns6 in the presence of MDL 72274 pretreatment. To
further confirm the inhibitory effect of MDL 72274 in
vivo, we studied the effect of this compound in the epidy-
dimal white adipose tissue homogenates, a tissue known to
be particularly rich in semicarbazide-sensitive benzylamine
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Fig. 1. Effect of a single i.p. injection of either saline, deprenyl 10 mg
y1 .  y1 .  y1 .kg , clorgyline 2.5 mg kg or MDL 72274 2.5 mg kg on
 .  .monoamine oxidase B MAO B , monoamine oxidase A MAO A and
 .semicarbazide-sensitive benzylamine oxidase Bz-SSAO activity in
mouse brain. The brains were removed and stored at y708C 2 h after the
injection, when the food consumption tests were completed. Values are
the means"S.E.M. of six experiments carried out in duplicate. Differ-
ences between groups were analyzed by Student’s paired two-tailed t-test.
) ) )  .P -0.001, P -0.05 compared with saline. Control ; clorgy-
 y1 .  .  y1 .  .line 2.5 mg kg ; deprenyl 10 mg kg ; MDL 72274
 y1 .  .2.5 mg kg .
oxidases. MDL 72274 reduced semicarbazide-sensitive
benzylamine oxidase activity in this tissue up to 85%, thus
more significantly than in the brain, controlss1238"7;
MDL 72274 pretreated s 183 " 9 nmol gy1 hy1;
.P-0.01; ns6 .
3.2. Feeding beha˝ior
In accordance with the results obtained from previous
 .work Ghelardini et al., 1997 , the 12-h food-deprived
mice showed an increase in the amount of food consumed
 .during the 60 min test 673"28 mgrmouse . This result
was significantly higher than that from control, non-food-
deprived animals 240"14 mgrmouse; P)0.001; ns
.  .20 . Tetraethylammonium 30 nmolrmouse i.c.v. or ben-
 .zylamine 226 nmolrmouse i.c.v. inhibited the food con-
sumption of 12-h food-deprived mice to about the same
 .extent Fig. 2 . The anorectic effect of tetraethyl-
ammonium and benzylamine was comparable to that ob-
tained with 5 nmol amphetamine given i.c.v. to mice.
Fig. 2 illustrates the hypophagic activity of these com-
pounds in the presence of a selective amine oxidase inhibi-
tion obtained with clorgyline, deprenyl and MDL 72274
administered i.p., 1 h before assessment of food consump-
tion. In these experiments, it was previously verified that,
as compared to that of the controls, pretreatment with these
inhibitors did not substantially affect the food consumption
of the animals. It is evident from Fig. 2 that monoamine
oxidase A and B inhibition both significantly potentiated
the anorectic effect of benzylamine and amphetamine,
while only the monoamine oxidase B inhibitor, deprenyl,
increased the effect of tetraethylammonium. Similar results
were obtained when Ro 16-6491, a selective monoamine
oxidase B inhibitor devoid of indirect sympathomimetic
 .activity, was used data not shown . Since the activity of
semicarbazide-sensitive benzylamine oxidases in the whole
brain tissues is low, it was perhaps not surprising that the
effect of the i.c.v.- injected benzylamine was unaffected by
pretreatment with the selective semicarbazide-sensitive
benzylamine oxidase inhibitor, MDL 72274.
As shown in Fig. 3, the i.p. pretreatment with deprenyl
significantly shifted to the left the dose–response curve for
the anorectic effect of benzylamine administered i.c.v., so
 .that the ED values CLs95% confidence intervals for50
this compound were reduced from 151.90 CLs35.04–
.  .658.60 to 2.22 CL s 0.58–8.46 nmolrmouse.
Monoamine oxidase B inhibition also decreased the ED50
 .of amphetamine approximately 10-fold data not shown .
The ability of semicarbazide-sensitive benzylamine oxi-
dases to control the anorectic effect of benzylamine was
also studied in experiments in which this compound was
administered i.p. With this route of administration, benzy-
 y1 .lamine 600 mg kg produced only minimal effects
when given alone; however, the MDL 72274 and deprenyl
pretreatment or a combination of both, shifted the benzy-
 .lamine dose–response curve to the left Fig. 4 . In agree-
ment with this the approximated ED values of benzy-50
lamine were reduced to 173.3, 85.2, 42.8 mg kgy1 in mice
Fig. 2. Effect of selective inhibition of monoamine oxidase A, monoamine
oxidase B and semicarbazide-sensitive benzylamine oxidases on food
intake of 12-h food-deprived mice after administration of benzylamine
 .  .  .226 nmol , tetraethylammonium 30 nmol and amphetamine 5 nmol .
Mice were i.c.v. injected with saline or drug solution 15 min before the
test. Amine oxidase inhibitors were administered 60 min before the
treatment with drugs. The food intake values were evaluated as the
accumulated amount of food eaten 60 min after the beginning of the test.
Vertical lines represent S.E.M.; the number of mice was between 10 and
20. Student’s t-test, q P -0.01 in comparison with saline-treated mice;
) P -0.01 in comparison with drug-treated mice without selective AO
 .  y1 .  . inhibition. Control ; deprenyl 10 mg kg ; clorgyline 10
y1 .  .  y1 .  .mg kg ; MDL 72274 2.5 mg kg .
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Fig. 3. The selective inhibition of monoamine oxidase B shifted the
dose–food consumption curves for i.c.v. injected benzylamine to the left
 .for 12-h food-deprived mice. Benzylamine –B– ; benzylamineq
 .  y1 .deprenyl –’– . Mice were injected with deprenyl 10 mg kg 1 h
before the test. Each point represents the mean value"S.E.M. for 10–20
mice.
pretreated with MDL 72274, deprenyl and deprenylq
MDL 72274, respectively. In order to confirm the role of
Fig. 4. Selective inhibition of monoamine oxidase B and semicarbazide-
sensitive benzylamine oxidases shifted the dose–food consumption curves
for i.p.-injected benzylamine to the left for 12-h food-deprived mice.
 .  y1 .  . Control –B– ; deprenyl 10 mg kg –v – ; MDL 72274 2.5 mg
y1 .  .  .kg –’– ; deprenylqMDL 72274 –%– . Mice were i.p. injected
with saline or benzylamine solution 15 min before the test. Amine
oxidase inhibitors were administered 60 min before treatment with benzy-
lamine. Each point represents the mean value"S.E.M. for 10–20
mice. )At this dosage general toxicity and motor incoordination were
observed.
semicarbazide-sensitive benzylamine oxidase inhibitors in
potentiating the pharmacological activity of benzylamine
 y1administered peripherally, the effect of B24 100 mg kg
.i.p. , another selective inhibitor of these enzymes, struc-
turally unrelated to MDL 72274, was also evaluated. After
 .Fig. 5. Modulation of the anorectic effect of amphetamine A and
 .benzylamine B induced by the 5-HT antagonist, WAY 100635 in1A
a-methyl-p-tyrosine- and clorgyline-pretreated mice. a-Methyl-p-tyrosine
and clorgyline were administered i.p. 2 and 1 h before the test, respec-
tively. WAY 100635 and amphetamine or benzylamine were given i.c.v.
in the same injection. Student’s t-test, ) P -0.01 in comparison with
amphetamine or benzylamine-treated mice; P^ -0.01 in comparison with
amphetamine or benzylamineqa-methyl-p-tyrosine-treated mice; 8P -
0.01 in comparison with amphetamine or benzylamineqa-methyl-p-
 .tyrosineqclorgyline-treated mice. Control ; benzylamine or am-
 .  .phetamine alone ; qa-methyl-p-tyrosine ; qclorgylineqa-
 .methyl-p-tyrosine ; qclorgylineqa-methyl-p-tyrosineqWAY 0.8
 .nmol .
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Table 1
Effect of benzylamine, amphetamine and other central dopamine and 5-HT modulators in mouse rota-rod test
Treatment Number of falls in 30 s
Before treatment After treatment
15 min 30 min 45 min
 .Saline 5 ml i.c.v. 3.1"0.3 1.8"0.3 1.4"0.2 0.8"0.2
 .Bz 226 nmol i.c.v. 2.9"0.2 1.7"0.3 1.1"0.5 1.1"0.5
y1 .Clorgyline 2.5 mg kg i.p. 3.3"0.2 2.5"0.4 1.8"0.5 1.4"0.3
y1 .MDL 2.5 mg kg i.p. 3.1"0.2 2.1"0.2 1.5"0.2 1.3"0.3
y1 .Deprenyl 10 mg kg i.p. 3.2"0.3 2.6"0.3 1.3"0.2 1.1"0.2
y1 y1 .  .Deprenyl 10 mg kg i.p. qBz 300 mg kg i.p. 3.3"0.3 2.3"0.5 1.9"0.3 1.5"0.2
y1 .  .Deprenyl 10 mg kg i.p. qBz 226 nmol i.c.v. 3.0"0.2 2.2"0.5 0.8"0.2 0.9"0.2
y1 y1 .  .Deprenyl 10 mg kg i.p. qMDL 2.5 mg kg i.p. q 2.5"0.3 2.1"0.4 0.9"0.2 0.5"0.2
y1 .Bz 100 mg kg i.p.
a a a .AMPH 5 nmol i.c.v. 2.4"0.3 3.1"0.3 3.3"0.4 2.7"0.4
y1 a,b a,b a,b .  .Deprenyl 10 mg kg i.p. qAMPH 5 nmol i.c.v. 2.2"0.3 3.9"0.4 4.2"0.4 3.8"0.4
y1 y1 b b b .  .ayMpT 100 mg kg i.p. qclorgyline 2.5 mg kg i.p. q 3.1"0.5 2.8"0.4 1.7"0.5 0.6"0.5
 .AMPH 5 nmol i.c.v.
AMPHsamphetamine, Bzsbenzylamine, a-MpTsa-methyl-p-tyrosine, MDLsMDL 72274. Each value represents the mean for 8–10 mice.
aP-0.01 in comparison with saline controls.
bP-0.05 in comparison with AMPHy treated mice.
 y1 .i.p. administration of benzylamine 300 mg kg , food
consumption was reduced from 624"19 to 225"37 and
321"31 mgrmouse in MDL 72274 and B24-pretreated
mice, respectively.
3.3. Pharmacological characterization of hypophagic ef-
fect of benzylamine
To gain more information on the nature of the neuro-
transmitters involved in the effect of benzylamine, we
compared its anorectic activity to that of amphetamine in
the presence of some pharmacological manipulations. Pre-
treatment with a-methyl-p-tyrosine 100 mg kgy1 i.p., 2 h
before the experiments, so as to decrease central cate-
 .cholaminergic activity, significantly reduced 61% , but
did not abolish, the effect of 5 nmol i.c.v. amphetamine
 .Fig. 5A . Remarkably, under these conditions, the residual
 .anorectic activity of amphetamine was potentiated 77%
by pretreatment of the animals with the monoamine oxi-
dase A inhibitor, clorgyline.
When the selective 5-HT receptor antagonist, WAY1A
 .100635 0.8 nmol , was co-administered with am-
phetamine, a significant potentiation of the anorectic effect
of 5 nmol i.c.v. amphetamine in mice pretreated with
a-methyl-p-tyrosineqclorgyline was observed, whereas
 . w w  .the 5-HT Ondansetron or 5-HT 1- 2 methylsulphonyl -3 4
x xamimo ethyl-4-piperidinyl methyl-5-fluoro-2-methoxy-
 .1H-indole-3-carboxylate hydrochloride GR125487 re-
 .ceptor antagonists were ineffective data not shown .
Treatment with the agonists alone and in combination with
a-methyl-p-tyrosine and clorgyline did not modify the
food intake with respect to that of the controls. The same
pharmacological treatments, allowed us to modulate the
anorexic effect of 226 nmol i.c.v. benzylamine in a similar
 .manner to that of amphetamine Fig. 5B .
3.4. Effects of treatments on mouse beha˝ior
The motor coordination of mice treated with benzy-
lamine, amphetamine, tetraethylammonium and other com-
pounds used in food consumption studies was evaluated.
 .Compared to controls, in the rota rod test Table 1 ,
benzylamine-treated mice were not impaired as to motor
coordination, as seen from the progressive reduction of the
number of falls of the animals, which indicated that the
mice had learned how to balance on the rotating rod. As
expected, the only exception was in the amphetamine-
treated group, where a significant, time-related increase in
the number of falls was measured. The motor incoordina-
tion induced by amphetamine was further potentiated by
deprenyl pretreatment, while it was abolished by the simul-
taneous administration of a-methyl-p-tyrosine. Similar re-
sults were obtained with the hole-board test data not
.shown , where again the amphetamine-, but not benzy-
lamine-treated animals, showed an increase in performance
which was completely abolished by a-methyl-p-tyrosine
treatment.
4. Discussion
These studies provide the first demonstration that ben-
zylamine, a substrate common to monoamine oxidase B
and semicarbazide-sensitive benzylamine oxidase en-
zymes, has anorectic properties in mice which are probably
due to the release of central catecholamines and 5-HT.
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The i.c.v. injections of benzylamine dose dependently
reduced the food intake in mice deprived of food for 12 h.
We injected benzylamine directly into the cerebral ventri-
cles in order to limit the activity to the central nervous
system and to exclude the role of peripheral mechanisms.
The selective inhibition of monoamine oxidase B signifi-
cantly potentiated the hypophagic effect of benzylamine
about 100-fold, while, as expected, considering the very
low activity of semicarbazide-sensitive benzylamine oxi-
dases in the brain, a similar effect was not detected during
pretreatment with the semicarbazide-sensitive benzylamine
oxidase inhibitor, MDL 72274. Significant differences from
the i.c.v. administration route were observed after i.p.
administration of benzylamine. In fact, the hypophagic
effect of this compound was progressively potentiated by
pretreatment with MDL 72274, deprenyl, or a combination
of these two inhibitors. This result showed a clear role of
semicarbazide-sensitive benzylamine oxidases, together
with monoamine oxidase B, in controlling the effect of
peripherally administered benzylamine.
After i.c.v. administration, the inhibition of monoamine
oxidase A or B strongly potentiated both the amphetamine
or benzylamine hypophagic response, whereas only
monoamine oxidase B inhibition significantly increased
the effect of tetraethylammonium. Some suggestions could
be made in order to explain these effects. It is well known
that a variety of neurotransmitters may decrease food
intake mainly by acting at the hypothalamic level; among
these dopamine and 5-HT, which are substrates of
monoamine oxidase B and A, respectively Moreley and
.Levine, 1985; Buffoni, 1995; Knoll, 1998 , have an impor-
tant role. It has also been shown that treatment with
monoamine oxidase inhibitors could induce anorectic ac-
tivity in animals by increasing the levels of 5-HT or
dopamine in the brain Gray et al., 1981; Gregory and
. qSmith, 1982; Aulakh et al., 1988 . K channel blockers
such as tetraethylammonium or 4-aminopyridine could also
increase the release of neurotransmitters Dawson and
.Routledge, 1995; Schechter, 1997 and inhibit feeding in
 .mice Ghelardini et al., 1997 . The potentiation induced by
deprenyl and the failure of clorgyline to increase the effect
of tetraethylammonium suggest that the anorectic activity
of this last compound preferentially involves dopaminergic
neurons. An attempt to highlight a serotoninergic, clorgy-
line-sensitive, component of the activity of tetraethyl-
 .ammonium by administering higher dosages 60 nmol of
this compound failed, because of its very strong motor
stimulatory activity. Taken together, these considerations
can reasonably explain the deprenyl and clorgyline-in-
duced potentiation of the hypophagic effects of tetraethyl-
ammonium, amphetamine and benzylamine as the inhibi-
tion of oxidative deamination of the neurotransmitters
released by these compounds. On the other hand, it is well
known that benzylamine but not tetraethylammonium or
.amphetamine is a substrate with good affinity for
monoamine oxidase B or semicarbazide-sensitive benzy-
 .lamine oxidase enzymes Buffoni, 1995 . Therefore, the
potentiation of the anorectic effect of benzylamine could
also be explained partly by the inhibition of oxidative
deamination, which leads to an increase in the central
concentrations of this compound.
In our experiments, we used deprenyl to selectively
inhibit monoamine oxidase B activity. It is well known
that this inhibitor is metabolized in vivo to L-amphetamine
 .derivatives Knoll, 1998 , which in turn should be respon-
sible for the potentiation of the anorectic activity observed
in our experiments. However, at the dosage utilized, de-
prenyl, clorgyline or MDL72274 alone did not reduce the
food consumption of the animals. A similar potentiation of
the anorectic effect of benzylamine was also observed in
animals pretreated with Ro 16-6491, a selective monoamine
 .oxidase B inhibitor Alemany et al. 1995 devoid of am-
phetamine-like activity, as well as with B24, a pyridine-de-
rived, semicarbazide-sensitive benzylamine oxidase in-
hibitor. This confirms that these effects were actually due
to a selective amine oxidases inhibition, and were unre-
lated to the chemical structure of the inhibitors.
As mentioned before, the potentiation of the anorectic
activity of amphetamine, after monoamine oxidase A or B
inhibition, suggests that the effect of these compounds is
probably linked to release of both dopamine and 5-HT.
Notwithstanding the fact that amphetamine is generally
regarded as an indirect dopaminergic compound, results of
studies combining microdialysis in the lateral hypothala-
mus with simultaneous infusion of amphetamine suggest
that serotoninergic mechanisms could also play a role. A
significant increase in the central levels of both dopamine
and 5-HT has been shown after amphetamine administra-
tion to experimental animals; a good correlation was estab-
lished between the anorectic activity of amphetamine and
the hypophagic effect induced by direct i.c.v. injections of
 .these two neurotransmitters Parada et al, 1988, 1992 . On
the other hand, the observation that, in mice and rats, 2- or
4-h pretreatment with a-methyl-p-tyrosine failed to antag-
onize or incompletely antagonized the anorectic effect of
amphetamine may be explained by an inadequate depletion
of central catecholamines, and also by the release of
non-catecholaminergic neurotransmitters Abdallah et al.,
.1976; Shucla et al., 1990 .
Investigations into the mechanism of the anorectic ac-
tion of our compounds, by direct measurement of
monoamine levels in the brain, surpassed the aim of the
present work which was mainly oriented at investigating
the behavioral effects of selective amine oxidase inhibi-
tion. However, a pharmacological characterization of the
effects induced by benzylamine in comparison with am-
phetamine was made in this work. Somatodendritic 5-HT1A
receptors in the raphe nuclei appear to play an important
role in controlling the hypophagic effect of different sero-
toninergic compounds. For example, recent findings have
established that blockade of 5-HT receptors with selec-1A
tive antagonists facilitates the effect of the indirectly acting
( )G. Banchelli et al.rEuropean Journal of Pharmacology 413 2001 91–9998
compounds, fenfluramine and fluoxetine, by means of a
 .rise in extracellular 5-HT Grignaschi, 1998 . On the con-
trary, reversal of anorexia induced by these compounds has
been obtained using the selective 5-HT receptor agonist,1A
 . 8-hydroxy-2- di-n-propylamino tetralin Currie et al.,
.1998 .
In our experiments, 100 mg kgy1 i.p. a-methyl-p-tyro-
sine given 2 h before the tests a dosage which did not
.modify basal food consumption significantly reduced the
anorectic effect of amphetamine and benzylamine. The
residual effect was potentiated by clorgyline and further
increased by 0.8 nmol i.c.v. of the 5-HT receptor antago-1A
nist, WAY 100635.
We can explain the effect observed with WAY 100635
by assuming that this compound antagonizes 5-HT1A
presynaptic receptors by increasing the amphetamine-in-
duced 5-HT release. Very similar results were observed
with benzylamine in the presence of the same pretreat-
ments. The effect of the presynaptically acting 5-HT recep-
tor antagonist, WAY 100635, is consistent with recent data
 .Grignaschi et al., 1998 obtained with different serotonin-
ergic anorectic compounds, and provides further evidence
that a part of the hypophagic activity of amphetamine and
benzylamine could be serotoninergic.
In the light of the results of experiments on motor
behavior, the major difference between amphetamine and
benzylamine is the absence of central stimulatory effects
for the latter compound. Relevant literature suggests that
the hyperactivity and motor incoordination induced by
amphetamine are mainly due to dopamine receptors Cole,
.1978; Aulakh et al., 1988 primarily located in the nigros-
triatal and mesolimbic systems. The observation that, in
a-methyl-p-tyrosine-pretreated mice, the motor stimulatory
effect induced by amphetamine was abolished confirms a
dominant dopaminergic activity for this compound, which
seems of minor importance for benzylamine, and indicates
that substantial dopamine depletion was obtained after
a-methyl-p-tyrosine pretreatment. The reason for the dis-
crepancy between the anorectic and motor stimulatory
activities observed with amphetamine and benzylamine
cannot be explained on the basis of the present experi-
ments. It is possible that some differences exist with regard
to the central brain region which controls feeding behavior
or motor activity, and related receptor types indirectly
stimulated by these two compounds at the doses used in
our experiments.
In summary and conclusion, we have now described the
anorectic activity of benzylamine, which seems to be
partly due to a release of 5-HT. In terms of the response to
amine oxidase inhibition and receptor antagonism it ap-
pears comparable to the effect of amphetamine. Our results
provide an in vivo experimental demonstration that selec-
tive inhibitors of peripheral semicarbazide-sensitive benzy-
lamine oxidases be of therapeutic value through increasing
the pharmacological effects of one of the best substrates of
these enzymes.
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